AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,165,291 | -24.5% | 612,739 | -13.7% | 0.00% | -25.0% |
| Q2 2023 | $20,098,930 | +29.8% | 709,708 | +5.2% | 0.00% | +33.3% |
| Q1 2023 | $15,488,878 | -19.9% | 674,309 | -2.1% | 0.00% | -25.0% |
| Q4 2022 | $19,347,597 | +1.6% | 689,017 | +2.4% | 0.00% | 0.0% |
| Q3 2022 | $19,035,000 | +61.5% | 673,073 | +26.6% | 0.00% | +33.3% |
| Q2 2022 | $11,783,000 | -24.7% | 531,446 | -1.1% | 0.00% | 0.0% |
| Q1 2022 | $15,641,000 | -24.7% | 537,323 | -15.0% | 0.00% | 0.0% |
| Q4 2021 | $20,783,000 | -25.5% | 632,287 | +4.6% | 0.00% | -40.0% |
| Q3 2021 | $27,904,000 | -18.4% | 604,637 | -2.5% | 0.01% | -16.7% |
| Q2 2021 | $34,179,000 | +127.2% | 620,192 | +112.9% | 0.01% | +100.0% |
| Q1 2021 | $15,045,000 | +21.4% | 291,371 | +1.9% | 0.00% | +50.0% |
| Q4 2020 | $12,388,000 | +22.7% | 285,888 | -0.9% | 0.00% | 0.0% |
| Q3 2020 | $10,094,000 | -38.1% | 288,400 | -5.4% | 0.00% | -50.0% |
| Q2 2020 | $16,299,000 | +35.8% | 304,777 | -9.9% | 0.00% | +33.3% |
| Q1 2020 | $12,006,000 | -21.6% | 338,381 | +5.5% | 0.00% | 0.0% |
| Q4 2019 | $15,320,000 | +62.3% | 320,839 | +10.1% | 0.00% | +50.0% |
| Q3 2019 | $9,442,000 | -36.8% | 291,418 | -2.7% | 0.00% | -50.0% |
| Q2 2019 | $14,947,000 | -10.9% | 299,654 | +20.5% | 0.00% | 0.0% |
| Q1 2019 | $16,776,000 | +48.5% | 248,746 | +1.5% | 0.00% | +33.3% |
| Q4 2018 | $11,296,000 | -40.3% | 244,974 | -0.2% | 0.00% | -40.0% |
| Q3 2018 | $18,934,000 | -9.7% | 245,509 | -1.4% | 0.01% | 0.0% |
| Q2 2018 | $20,973,000 | -4.7% | 248,989 | -7.5% | 0.01% | -16.7% |
| Q1 2018 | $22,008,000 | +65.0% | 269,108 | +15.3% | 0.01% | +100.0% |
| Q4 2017 | $13,342,000 | -12.6% | 233,400 | +2.1% | 0.00% | -25.0% |
| Q3 2017 | $15,261,000 | +27.4% | 228,626 | -1.8% | 0.00% | +33.3% |
| Q2 2017 | $11,977,000 | +15.7% | 232,802 | +31.3% | 0.00% | 0.0% |
| Q1 2017 | $10,350,000 | +56.5% | 177,242 | +11.8% | 0.00% | +50.0% |
| Q4 2016 | $6,614,000 | -17.3% | 158,497 | +4.6% | 0.00% | 0.0% |
| Q3 2016 | $8,000,000 | +53.6% | 151,467 | +21.8% | 0.00% | 0.0% |
| Q2 2016 | $5,208,000 | +14.9% | 124,316 | +11.4% | 0.00% | 0.0% |
| Q1 2016 | $4,532,000 | -41.0% | 111,629 | -5.6% | 0.00% | -33.3% |
| Q4 2015 | $7,680,000 | -9.0% | 118,294 | -1.1% | 0.00% | 0.0% |
| Q3 2015 | $8,441,000 | -51.6% | 119,569 | -23.9% | 0.00% | -40.0% |
| Q2 2015 | $17,452,000 | +5.4% | 157,030 | -10.6% | 0.01% | 0.0% |
| Q1 2015 | $16,562,000 | -10.3% | 175,635 | +6.6% | 0.01% | -16.7% |
| Q4 2014 | $18,466,000 | +106.5% | 164,820 | +13.1% | 0.01% | +100.0% |
| Q3 2014 | $8,944,000 | +95.8% | 145,784 | +46.2% | 0.00% | +200.0% |
| Q2 2014 | $4,568,000 | +30.4% | 99,693 | +11.5% | 0.00% | 0.0% |
| Q1 2014 | $3,502,000 | +53.3% | 89,449 | -6.3% | 0.00% | 0.0% |
| Q4 2013 | $2,285,000 | +129.6% | 95,430 | +168.1% | 0.00% | – |
| Q3 2013 | $995,000 | – | 35,593 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |